Advertisement

Advertisement
Solange Peters, MD, PhD, on NSCLC: CheckMate 227 Trial of Nivolumab/Ipilimumab vs Chemotherapy

Solange Peters, MD, PhD, on NSCLC: CheckMate 227 Trial of Nivolumab/Ipilimumab vs Chemotherapy

FLAURA Trial: First-Line Osimertinib Improves Overall Survival in EGFR-Mutated Advanced Lung Cancer

FLAURA Trial: First-Line Osimertinib Improves Overall Survival in <em>EGFR</em>-Mutated  Advanced Lung Cancer

First-line treatment with osimertinib extended overall survival compared with the older tyrosine kinase inhibitors gefitinib and erlotinib...

CASPIAN Trial: Addition of Durvalumab to Platinum/Etoposide for First-Line Treatment of Extensive-Stage SCLC

CASPIAN Trial: Addition of Durvalumab to Platinum/Etoposide for First-Line Treatment of Extensive-Stage SCLC

As reported in The Lancet by Luis Paz-Ares, MD, and colleagues, an interim analysis of the phase III CASPIAN trial has shown an overall survival benefit with the addition of durvalumab to platinum/etoposide chemotherapy in the first-line treatment of extensive-stage small cell lung cancer (SCLC).

RELAY Trial: Addition of Ramucirumab to Erlotinib in Previously Untreated, EGFR-Mutated Advanced NSCLC

As reported in The Lancet Oncology by Nakagawa et al, the phase III RELAY trial has shown that the addition of ramucirumab to erlotinib improved progression-free survival in treatment-naive, advanced EGFR-mutated non–small cell lung cancer (NSCLC).

Patient-Reported Outcomes Observed With Durvalumab Treatment After Chemoradiotherapy for Stage III Unresectable NSCLC

As reported in The Lancet Oncology by Hui et al, no clinically important differences in patient-reported outcomes were observed among patients receiving durvalumab vs placebo after chemoradiation for stage III unresectable non–small cell lung cancer (NSCLC) in the phase III PACIFIC trial.

IASLC North America: Lung Cancer Screening Among First Responders

National lung cancer screening guidelines are inadequate to diagnose patients who contract lung cancer from occupational exposure, including first responders, according to a study reported by Vershalee Shukla, MD, at the International Association for the Study of Lung Cancer’s (IASLC) North America Conference on Lung Cancer.

Advertisement


Advertisement